{"id":"https://openalex.org/W1925223276","doi":"https://doi.org/10.1200/jco.1996.14.2.610","title":"Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer.","display_name":"Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer.","publication_year":1996,"publication_date":"1996-02-01","ids":{"openalex":"https://openalex.org/W1925223276","doi":"https://doi.org/10.1200/jco.1996.14.2.610","mag":"1925223276","pmid":"https://pubmed.ncbi.nlm.nih.gov/8636778"},"language":"en","primary_location":{"id":"doi:10.1200/jco.1996.14.2.610","doi":"https://doi.org/10.1200/jco.1996.14.2.610","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.1996.14.2.610","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5073788838","display_name":"D.J. Boote","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I90344618","display_name":"Medical Research Council","ror":"https://ror.org/03x94j517","country_code":"GB","type":"government","lineage":["https://openalex.org/I4210087105","https://openalex.org/I90344618"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"D J Boote","raw_affiliation_strings":["Medical Research Council Unit, Medical Research Council Centre, Cambridge, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Research Council Unit, Medical Research Council Centre, Cambridge, United Kingdom","institution_ids":["https://openalex.org/I90344618"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5013043745","display_name":"Ian F. Dennis","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"I F Dennis","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108218539","display_name":"Peter R. Twentyman","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"P R Twentyman","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108085607","display_name":"Richard J. Osborne","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"R J Osborne","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5027707539","display_name":"C. LABURTE","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"C Laburte","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5007097714","display_name":"S. Hensel","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"S Hensel","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109159321","display_name":"J F Smyth","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"J F Smyth","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5105884746","display_name":"MH Brampton","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"M H Brampton","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5113529484","display_name":"N M Bleehen","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"N M Bleehen","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":8.3744,"has_fulltext":false,"cited_by_count":172,"citation_normalized_percentile":{"value":0.98045012,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":88,"max":98},"biblio":{"volume":"14","issue":"2","first_page":"610","last_page":"618"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10570","display_name":"Drug Transport and Resistance Mechanisms","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10570","display_name":"Drug Transport and Resistance Mechanisms","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.00039999998989515007,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11845","display_name":"Cancer therapeutics and mechanisms","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/etoposide","display_name":"etoposide","score":0.9049999713897705},{"id":"https://openalex.org/keywords/multidrug-resistance","display_name":"multidrug resistance","score":0.7400000095367432},{"id":"https://openalex.org/keywords/psc-833","display_name":"PSC833","score":0.7080000042915344},{"id":"https://openalex.org/keywords/maximum-tolerated-dose","display_name":"maximum tolerated dose","score":0.7289999723434448},{"id":"https://openalex.org/keywords/continuous-infusion","display_name":"continuous infusion","score":0.609000027179718},{"id":"https://openalex.org/keywords/myelosuppression","display_name":"myelosuppression","score":0.8560000061988831},{"id":"https://openalex.org/keywords/hyperbilirubinemia","display_name":"hyperbilirubinemia","score":0.9760000109672546},{"id":"https://openalex.org/keywords/ataxia","display_name":"ataxia","score":0.9399999976158142},{"id":"https://openalex.org/keywords/drug-drug-interactions","display_name":"drug-drug interactions","score":0.6589999794960022},{"id":"https://openalex.org/keywords/cancer-chemotherapy","display_name":"cancer chemotherapy","score":0.5690000057220459},{"id":"https://openalex.org/keywords/dose-escalation","display_name":"dose escalation","score":0.5009999871253967},{"id":"https://openalex.org/keywords/steady-state-drug-concentration","display_name":"steady-state drug concentration","score":0.49300000071525574}],"concepts":[{"id":"https://openalex.org/C2778119113","wikidata":"https://www.wikidata.org/wiki/Q418817","display_name":"Etoposide","level":3,"score":0.8695052862167358},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8640011548995972},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.7185316681861877},{"id":"https://openalex.org/C29730261","wikidata":"https://www.wikidata.org/wiki/Q274160","display_name":"Toxicity","level":2,"score":0.698120653629303},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.3808554410934448},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.3769550025463104},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.36146777868270874},{"id":"https://openalex.org/C126894567","wikidata":"https://www.wikidata.org/wiki/Q105650","display_name":"Urology","level":1,"score":0.35596179962158203},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.30831530690193176}],"mesh":[{"descriptor_ui":"D000293","descriptor_name":"Adolescent","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000972","descriptor_name":"Antineoplastic Agents, Phytogenic","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D000972","descriptor_name":"Antineoplastic Agents, Phytogenic","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000972","descriptor_name":"Antineoplastic Agents, Phytogenic","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D003524","descriptor_name":"Cyclosporins","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D003524","descriptor_name":"Cyclosporins","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D005047","descriptor_name":"Etoposide","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D005047","descriptor_name":"Etoposide","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006207","descriptor_name":"Half-Life","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D018432","descriptor_name":"Drug Resistance, Multiple","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1200/jco.1996.14.2.610","doi":"https://doi.org/10.1200/jco.1996.14.2.610","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.1996.14.2.610","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},{"id":"pmid:8636778","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/8636778","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","raw_type":"Clinical Trial"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9940000176429749,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":21,"referenced_works":["https://openalex.org/W1537239037","https://openalex.org/W1547342210","https://openalex.org/W1754065147","https://openalex.org/W1927327874","https://openalex.org/W1945936026","https://openalex.org/W1958840615","https://openalex.org/W1964470226","https://openalex.org/W1996312633","https://openalex.org/W2016756053","https://openalex.org/W2024463580","https://openalex.org/W2025603165","https://openalex.org/W2037621239","https://openalex.org/W2041209857","https://openalex.org/W2099659016","https://openalex.org/W2100686920","https://openalex.org/W2104733808","https://openalex.org/W2135859599","https://openalex.org/W2138993111","https://openalex.org/W2507629633","https://openalex.org/W2615953705","https://openalex.org/W3111650914"],"related_works":["https://openalex.org/W1967728998","https://openalex.org/W2054957236","https://openalex.org/W1900236741","https://openalex.org/W1875749271","https://openalex.org/W2160678909","https://openalex.org/W2255683021","https://openalex.org/W2086399030","https://openalex.org/W1975396640","https://openalex.org/W1854257098","https://openalex.org/W1983186379"],"abstract_inverted_index":{"PURPOSE:":[0],"To":[1],"determine":[2,25],"the":[3,26,42,148,192,216],"maximum-tolerated":[4],"dose":[5,65,82,280],"(MTD)":[6],"and":[7,23,83,99,117,188,198,239,249,260,302],"toxicity":[8,155,170],"of":[9,28,45,66,114,156,166,171,181,191,219,227,233,237,252,258,281],"PSC":[10,29,71,115,121,135,157,172,201,264,282,293,311],"833":[11,30,72,116,122,136,158,173,202,265,283,294],"infusion":[12,58,279],"administered":[13,74,268],"with":[14,21,111,271,273],"etoposide":[15,32,213,224,272,300,303],"for":[16,284],"5":[17,60,291],"days":[18,62],"in":[19,130,164,179,189,209,212,223,231,243,269,296,299,308],"patients":[20,38,108,132,183,194,309],"cancer,":[22],"to":[24,68,94,101],"effect":[27],"on":[31],"pharmacokinetics.":[33],"PATIENTS":[34],"AND":[35],"METHODS:":[36],"Thirty-five":[37],"were":[39,90,109,128],"entered":[40],"onto":[41],"study,":[43],"one":[44],"whom":[46],"was":[47,50,73,147,159,174],"ineligible.":[48],"Etoposide":[49],"delivered":[51],"from":[52,75,92],"day":[53,76],"1":[54,93,100],"as":[55,78,84],"a":[56,64,79,85,221,229],"2-hour":[57,80],"over":[59,290],"consecutive":[61],"at":[63,134,185,196],"75":[67],"100":[69],"mg/m2/d.":[70],"2":[77,95],"loading":[81],"5-day":[86],"continuous":[87,144,278],"infusion.":[88,145],"Doses":[89],"escalated":[91],"mg/kg":[96],"(loading":[97],"dose)":[98],"15":[102,199],"mg/kg/d":[103,142,187,289],"(continuous":[104],"infusion).":[105],"RESULTS:":[106],"Thirty-four":[107],"treated":[110,133,184,195],"53":[112],"cycles":[113],"etoposide.":[118],"Steady-state":[119],"blood":[120],"levels":[123],"more":[124,204],"than":[125,205],"1,000":[126],"ng/mL":[127,207],"achieved":[129],"all":[131],"doses":[137,304],">":[138],"or":[139],"=":[140],"6.6":[141],"by":[143],"Myelosuppression":[146],"most":[149],"common":[150],"toxicity.":[151,275],"The":[152,168,276],"major":[153],"dose-related":[154],"reversible":[160],"hyperbilirubinemia,":[161],"which":[162,177],"occurred":[163,178],"83%":[165],"cycles.":[167],"dose-limiting":[169],"severe":[175],"ataxia,":[176],"two":[180],"nine":[182],"12":[186],"both":[190],"single":[193],"13.5":[197],"mg/kg/d.":[200],"concentrations":[203],"2,000":[206],"resulted":[208],"an":[210,240,297],"increase":[211,242,251,298],"area":[214],"under":[215],"curve":[217],"(AUC)":[218],"89%,":[220],"decrease":[222,230],"clearance":[225],"(Cl)":[226],"45%,":[228],"volume":[232],"steady-state":[234],"distribution":[235],"(Vss)":[236],"41%,":[238],"insignificant":[241],"alpha":[244],"half-life":[245,254],"(t":[246,255],"1/2":[247,256],"alpha)":[248],"significant":[250],"beta":[253],"beta)":[257],"19%":[259],"77%,":[261],"respectively.":[262],"CONCLUSION:":[263],"can":[266],"be":[267,306],"combination":[270],"acceptable":[274],"recommended":[277],"this":[285],"schedule":[286],"is":[287],"10":[288],"days.":[292],"results":[295],"exposure":[301],"should":[305],"reduced":[307],"receiving":[310],"833.":[312]},"counts_by_year":[{"year":2023,"cited_by_count":1},{"year":2022,"cited_by_count":1},{"year":2021,"cited_by_count":1},{"year":2020,"cited_by_count":2},{"year":2019,"cited_by_count":1},{"year":2018,"cited_by_count":1},{"year":2017,"cited_by_count":2},{"year":2016,"cited_by_count":2},{"year":2015,"cited_by_count":4},{"year":2014,"cited_by_count":5},{"year":2013,"cited_by_count":2},{"year":2012,"cited_by_count":4}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}